Investors

Print Page Print Page | E-mail Page E-mail Page | RSS Feeds RSS Feeds

AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain. AcelRx's lead product candidate, Zalviso, is designed to solve the problems associated with post-operative intravenous patient-controlled analgesia which has been shown to cause harm to patients following surgery because of the side effects of morphine, the invasive IV route of delivery and the complexity of infusion pumps. AcelRx has announced positive results from each of the three Phase 3 clinical trials for Zalviso and has submitted an NDA to the FDA seeking its approval. AcelRx also announced positive top-line results for a Phase 2 trial for ARX-04, a sufentanil formulation for the treatment of moderate-to-severe acute pain, funded through a grant from U.S. Army Medical Research and Materiel Command. The company has two additional pain treatment product candidates, ARX-02 and ARX-03, which have completed Phase 2 clinical development.
ACRX (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$7.47
Change (%) Stock is Up 0.32 (4.48%)
Volume642,562
Data as of 09/02/14 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote

Recent News

    More >>
08/27/14AcelRx Pharmaceuticals to Participate in Two Upcoming Investor Events
REDWOOD CITY, Calif., Aug. 27, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that senior management will be participating at the FBR Healthcare One on One Conference and presenting at the Morgan Stanley Global Healthcare Conference.  Details of the two events are as follows: FBR Healthcare One on One C... 
Printer Friendly Version
08/11/14AcelRx Pharmaceuticals Reports Second Quarter 2014 Financial Results
REDWOOD CITY, Calif., Aug. 11, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today reported financial results for the three and six months ended June 30, 2014.  On July 25, 2014, AcelRx announced that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) for the Company's new drug ... 
Printer Friendly Version
08/08/14AcelRx Pharmaceuticals to Participate in Three Upcoming Investor Events
REDWOOD CITY, Calif., Aug. 8, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that senior management will be participating at three upcoming investor events. Details of the three events are as follows: Canaccord 34th Annual Growth Conference Date: Wednesday August 13th Location: Boston, MA Presentati... 
Printer Friendly Version

Upcoming Events

    More >>
DateTitle
09/03/14
AcelRx Pharmaceuticals, Inc. at the FBR Healthcare One on One Conference
LocationFour Seasons
Boston, MA
09/10/14 1:30 p.m. ET
AcelRx Pharmaceuticals, Inc. at Morgan Stanley Healthcare Conference
LocationNew York, NY US

Receive E-mail Alerts 

Sign up to receive e-mail alerts whenever AcelRx Pharmaceuticals, Inc. posts new information to the site. Just enter your e-mail address and click Submit.
 

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

AcelRX

CONTACT